Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2)

被引:95
作者
Hanke, Ulrike [1 ]
May, Karen [2 ]
Rozehnal, Veronika [2 ]
Nagel, Stefan [1 ]
Siegmund, Werner [2 ]
Weitschies, Werner [1 ]
机构
[1] Ernst Moritz Arndt Univ Greifswald, Inst Pharm, Dept Biopharmaceut & Pharmaceut Technol, D-17487 Greifswald, Germany
[2] Ernst Moritz Arndt Univ Greifswald, Dept Clin Pharmacol, Inst Pharmacol, D-17487 Greifswald, Germany
关键词
Surfactant; Efflux transporter; ABCB1 (p-gp); ABCC2 (MRP2); MDCK cells; MULTIDRUG-RESISTANCE PROTEIN-2; CACO-2 CELL MONOLAYERS; ORAL-DRUG ABSORPTION; IN-VIVO; CYCLOSPORINE-A; CREMOPHOR EL; PLURONIC P85; REVERSAL; RATS; PHARMACOKINETICS;
D O I
10.1016/j.ejpb.2010.06.008
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2) play an essential role in the limitation of oral bioavailability of drugs. In the last years, pharmaceutical surfactants like cremophor (R) EL or polysorbate 80 have been shown to interact with ABCB1. However, the knowledge about their influence on ABCC2 is still limited. In this study, the interactions of the nonionic surfactants cremophor (R) EL, cremophor (R) RH 40. polysorbate 80, vitamin E TPGS 1000, pluronic (R) PE 10300 and sucrose ester L-1695 with both efflux transporters were investigated on cellular level. Cell accumulation studies and transport studies were performed using transfected MOCK II cell models. The influence of ABCC2 inhibiting surfactants on the expression level of ABCC2 was also studied. The investigations showed that cremophor (R) EL, vitamin E TPGS 1000 and higher concentrations of polysorbate 80 inhibit both transporters. Pluronic (R) PE 10300 and sucrose ester L-1695 inhibit ABCB1 but not ABCC2. Cremophor (R) RH 40 only shows inhibitory activity on ABCC2. During the investigated incubation period none of the inhibiting surfactants caused an alteration in ABCC2mRNA or protein expression. These findings indicate that the observed interactions are caused by specific inhibition of the transport activity of ABCC2. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:260 / 268
页数:9
相关论文
共 49 条
[1]
Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein [J].
Adachi, Y ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1660-1668
[2]
EPITHELIAL TRANSPORT OF DRUGS IN CELL-CULTURE .1. A MODEL FOR STUDYING THE PASSIVE DIFFUSION OF DRUGS OVER INTESTINAL ABSORPTIVE (CACO-2) CELLS [J].
ARTURSSON, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (06) :476-482
[3]
Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO
[4]
2-J
[5]
Effect of pluronic p85 on ATPase activity of drug efflux transporters [J].
Batrakova, EV ;
Li, S ;
Li, YL ;
Alakhov, VY ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 2004, 21 (12) :2226-2233
[6]
Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells [J].
Batrakova, EV ;
Li, S ;
Alakhov, VY ;
Miller, DW ;
Kabanov, AV .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :845-854
[7]
Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85 [J].
Batrakova, EV ;
Li, S ;
Alakhov, VY ;
Elmquist, WF ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 2003, 20 (10) :1581-1590
[8]
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins [J].
Bogman, K ;
Erne-Brand, F ;
Alsenz, J ;
Drewe, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (06) :1250-1261
[9]
The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability [J].
Chan, LMS ;
Lowes, S ;
Hirst, BH .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (01) :25-51
[10]
Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) rnRNA and hepatic induction of mrp3 by constitutive androstane receptor activators in rats [J].
Cherrington, NJ ;
Hartley, DP ;
Li, N ;
Johnson, DR ;
Klaassen, CD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (01) :97-104